Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
about
Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease.Recent advances in CKD and ESRD: A literature update.Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease.HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolismIron Balance and the Role of Hepcidin in Chronic Kidney DiseaseNotch Downregulation and Extramedullary Erythrocytosis in Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 2-Deficient Mice.Renal Hypoxia in CKD; Pathophysiology and Detecting Methods.Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.Current and future chemical therapies for treating anaemia in chronic kidney disease.Expanding roles of the hypoxia-response network in chronic kidney disease.Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?Prolyl-hydroxylase inhibition induces SDF-1 associated with increased CXCR4+/CD11b+ subpopulations and cardiac repairInvestigational therapies for renal disease-induced anemia.A mechanistic link between renal ischemia and fibrosis.Hypoxia-dependent regulation of inflammatory pathways in immune cellsA New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat.Emerging drugs for the treatment of kidney disease-induced anemia.Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.Hypoxia Inducible Factor (HIF) Hydroxylases as Regulators of Intestinal Epithelial Barrier Function.Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases.Cooperative Oxygen Sensing by the Kidney and Carotid Body in Blood Pressure Control.The Dawning of a New Day in CKD Anemia Care?Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.Hydroxylase inhibition regulates inflammation-induced intestinal fibrosis through the suppression of ERK-mediated TGF-β1 signaling. [corrected].Mechanisms and mediators of hypertension induced by erythropoietin and related molecules.Induction of erythropoietin gene expression in epithelial cells by chemicals identified in GATA inhibitor screenings.Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.Hypoxia and hypoxia inducible factor-1α are required for normal endometrial repair during menstruation.Hypoxia Induced Factor in Chronic Kidney Disease: Friend or Foe?The safety of available treatment options for iron-deficiency anemia.Roxadustat in the treatment of anaemia in chronic kidney disease.Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders.Anemia in chronic kidney disease.Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson's Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function.An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects.The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney diseaseImpact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease
P2860
Q30251565-6C67CC2E-078A-4D2D-BC2E-ED33480D62A3Q30275339-0D0FD46E-7891-4484-84F5-6AE7AFD3D433Q33754900-9F9603EE-C6F4-4CB5-909D-8258745C5D12Q33926530-527DD8DA-415C-4BB3-BC51-A8B854D310E6Q36945750-634EA361-5611-4224-A69E-9A211E751B60Q37559382-6A9D92FF-7937-4000-A22B-8C36A5769A2AQ37653803-480E59FD-D15E-4CD1-BCFD-DA95935A6D96Q37705646-99AB4AD9-82A5-46FB-ADFA-DBD71DEC4A44Q38690858-A51692FF-95F2-4518-89CE-748E3E781B99Q38726764-4557C157-E549-460B-A538-D816B8009BA0Q38740776-934CA383-F2BA-40ED-928C-1F9B2C8AD66DQ38760612-C866ADA2-9468-464C-93CF-2B25FF2670E8Q38819455-F031AA19-5E9B-4195-9D34-546CAAC5E555Q38903388-E0FB9D0C-84E4-4080-9D3E-62E761551E95Q38907502-622FD79D-35AD-4396-A752-9436C4E0150BQ38909908-01A3B5FF-FB63-44C3-9EF6-93053FEACB35Q38930912-AFB6219C-838A-4753-9601-B9EA2B03B865Q39101277-574B1D4B-407D-40A2-A3FF-B669BD4DD4BCQ39277299-1A0757C2-01D2-45F6-97AF-8708E577A91DQ39291945-C271DD92-B09E-4DA5-BF73-BBDA941E0A25Q41161788-3A0D5F94-7003-48DC-BDA1-83A3C71DBD5FQ42372768-8E8DAF02-10EF-443B-9472-565217EDEF80Q42925622-A2E8EB32-BA0C-42C6-9A84-F22FED90AAFAQ46258639-9F92F845-8B44-4373-B10F-ED584FF44E1FQ46623958-0BBA8598-6336-4FCB-A345-1C3A9BEF13FEQ47307152-5E89A106-1B61-4BA8-ABEA-C628B843A21BQ47634204-67AAFB6D-5485-429F-9B0D-14E9390CBDFCQ48140646-6AC620FF-DC61-4F89-9111-08095FEAAAC6Q48181401-999D07D3-9CF1-4227-B479-0DA042B9364DQ48512043-542D2ACC-376F-48E5-854B-EF5783BB4C78Q48548255-279F04E8-A638-49FA-9CB7-A9FB92A9651AQ49649941-5B0321A4-B06B-4AD5-8D12-D83183AF16D5Q52381914-85F439C6-F5CC-459C-8651-4F5D60DCC3BDQ53354670-D1E62EB4-92CF-4C55-BA3C-94A1FC9C8143Q53383073-2E0D446A-F737-4226-BEA1-97220B48D5F7Q54979172-504890F1-BD04-43F4-8031-C112398AF90FQ55509823-61ABABAA-AB10-49BE-B97D-BE59032B682DQ57073613-B497D428-E76C-4249-B838-C607CC04FFF4Q58700150-65750709-3092-4B52-8EC0-7569034157F2
P2860
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
@ast
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
@en
type
label
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
@ast
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
@en
prefLabel
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
@ast
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
@en
P2093
P2860
P356
P1476
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
@en
P2093
Anatole Besarab
Elena Chernyavskaya
Evgeny Shutov
Igor Motylev
Khalil G Saikali
Kin-Hung Peony Yu
Konstantin Gurevich
Lalathaksha M Kumbar
Lona Poole
Marietta Franco
P2860
P304
P356
10.1681/ASN.2015030241
P50
P577
2015-10-22T00:00:00Z